Letter to the Editor: In Response to Hematology...Literally and Seriously
Dr. Rosenblum responds to The Hematologist Editor-in-Chief's commentary in the Year's Best issue.
A New Phase II Agent Holds Promise for First FDA Approved Therapy for Treatment of Acute Vaso-Occlusive Pain Events in SCD
Dr. DeBaun evaluates a new agent for the prevention of vaso-occlusive pain episodes in sickle cell disease that holds promise for first FDA approval since hydroxyurea.
A collection of issues of The Hematologist dating back to 2004. Contact Juana Llorens, Managing Editor, at email@example.com to request a copy of an earlier issue.
March-April 2017Volume 14, Issue 2
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology